Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?

Clinical Genitourinary Cancer

Volumn 14, Issue 2, 2016, Pages 183-187

  Mukherji, Deborah ^a   Jabbour, Mark N ^a   Saroufim, Maya ^a   Temraz, Sally ^a   Nasr, Rami ^a   Charafeddine, Maya ^a   Assi, Rita ^a   Shamseddine, Ali ^a   Tawil, Ayman N ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

5H1; Bladder cancer; Checkpoint inhibitors; PD 1; PD L1

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PARAFFIN; TUMOR MARKER; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CYSTECTOMY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; PATIENT SELECTION; PRIMARY TUMOR; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VERY ELDERLY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; URINARY BLADDER NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CYSTECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84960413790     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.12.002     Document Type: Article

References (12)

1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
2. C. Blank, T.F. Gajewski, and A. Mackensen Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 54 2005 307 314
3. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
4. J.M. Taube, A.P. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
5. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
6. T. Powles, J.P. Eder, G.D. Fine, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
7. E. Pilmack, S. Gupta, J. Bellmunt, and et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) (abstract LBA23) Ann Oncol 25 2014 1 41
8. K.D. Powderly, H. Koeppen, F.S. Hodi, and et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study (abstract 3001) J Clin Oncol 31 2013
9. R.H. Thompson, S.M. Kuntz, B.C. Leibovich, and et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
10. S.A. Boorjian, Y. Sheinin, P.L. Crispen, and et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival Clin Cancer Res 14 2008 4800 4808
11. J. Bellmunt, S.A. Mullane, L. Werner, and et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma Ann Oncol 26 2015 812 817
12. L.B. Jilaveanu, B. Shuch, C.R. Zito, and et al. PD-L1 Expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases J Cancer 5 2014 166 172